A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria

Shanks, G. Dennis, Oloo, Aggrey J., Aleman, Gladys M., Ohrt, Colin, Klotz, Francis W., Braitman, David, Horton, John and Brueckner, Ralf (2001) A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clinical Infectious Diseases, 33 12: 1968-1974. doi:10.1086/324081


Author Shanks, G. Dennis
Oloo, Aggrey J.
Aleman, Gladys M.
Ohrt, Colin
Klotz, Francis W.
Braitman, David
Horton, John
Brueckner, Ralf
Title A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria
Formatted title
A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria
Journal name Clinical Infectious Diseases   Check publisher's open access policy
ISSN 1058-4838
1537-6591
Publication date 2001-12-15
Sub-type Article (original research)
DOI 10.1086/324081
Open Access Status Not yet assessed
Volume 33
Issue 12
Start page 1968
End page 1974
Total pages 7
Place of publication Cary, NC, United States
Publisher Oxford University Press
Language eng
Formatted abstract
We tested tafenoquine (WR 238605), a new long-acting 8-aminoquinoline, for its ability to prevent malaria in an area that is holoendemic for Plasmodium falciparum. In a double-blinded, placebo-controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of 250 mg halofantrine per day for 3 days, to effect clearance of preexisting parasites. The volunteers were then assigned to 1 of 4 drug regimens: placebo throughout; 3 days of 400 mg (base) of tafenoquine per day, followed by placebo weekly; 3 days of 200 mg of tafenoquine per day, followed by 200 mg per week; and 3 days of 400 mg of tafenoquine per day, followed by 400 mg per week. Prophylaxis was continued for up to 13 weeks. Of the evaluable subjects (223 of 249 randomized subjects), volunteers who received 400 mg tafenoquine for only 3 days had a protective efficacy of 68% (95% confidence interval [CI], 53%-79%), as compared with placebo recipients; those who received 200 mg per day for 3 days followed by 200 mg per week had a protective efficacy of 86% (95% CI, 73%-93%); and those who received 400 mg for 3 days followed by 400 mg per week had a protective efficacy of 89% (95% CI, 77%-95%). A similar number of volunteers in the 4 treatment groups reported adverse events. Prophylactic regimens of 200 mg or 400 mg of tafenoquine, taken weekly for ≤13 weeks, are highly efficacious in preventing falciparum malaria and are well tolerated.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 81 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 105 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 05 May 2014, 22:00:58 EST by Ms Kate Rowe on behalf of Scholarly Communication and Digitisation Service